Cardiovascular risk and spondylitis, beyond anti-inflammatory drugs [PDF]
Trabajo de fin de grado. Grado en Medicina. Curso académico 2024-2025[ES]Introducción: La Espondilitis Anquilosante (EA) es una enfermedad reumática con una prevalencia de un 0.3% de la población, afectando principalmente a pacientes jóvenes.
Vílchez Fernández, José Luis
core
Comorbidities in Argentine patients with axial spondyloarthritis: Is nephrolithiasis associated with this disease? [PDF]
Sommerfleck F, Schneeberger E, Citera G.
europepmc +1 more source
Atlas de espondiloartritis axial en España: radiografía de la enfermedad
Proyecto impulsado por la Coordinadora Española de Asociaciones de Pacientes de Espondiloartritis (CEADE)
openaire +2 more sources
[Usefulness and reliabitlity of musculoskeletal point of care ultrasound in family practice (2): Muscle injuries, osteoarthritis, rheumatological diseases and eco-guided procedures]. [PDF]
Sánchez Barrancos IM +6 more
europepmc +1 more source
Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. [PDF]
Landi M +19 more
europepmc +1 more source
Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients. [PDF]
Garrido-Cumbrera M +8 more
europepmc +1 more source
Caracterización clínica y terapéutica de la Espondilitis Anquilosante. [PDF]
Ankylosing spondylitis (AS) is a chronic inflammatory pathology; its development depends on the predisposition, age, sex and family history of each patient.
Caguano Cudco, Edilvanny Marisol +1 more
core
Results from Polish Spondyloarthritis Initiative registry (PolSPI) - methodology and data from - the first year of observation. [PDF]
Guła Z +19 more
europepmc +1 more source
The role of smoking in the development and progression of structural damage in axial SpA patients: A systematic review and meta-analysis. [PDF]
Akar S +6 more
europepmc +1 more source

